Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Double Bond Pharmaceutical International AB FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Double Bond Pharmaceutical International AB FCF Yield % Related Terms
Double Bond Pharmaceutical International AB FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Double Bond Pharmaceutical International AB FCF Yield % Chart
Double Bond Pharmaceutical International AB Annual Data
XSAT:DBP B vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, Double Bond Pharmaceutical International AB's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Double Bond Pharmaceutical International AB FCF Yield % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Double Bond Pharmaceutical International AB (XSAT:DBP B) has a FCF Yield % of -15.56 as of Jul. 21, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Double Bond Pharmaceutical International AB and its competitors. According to the industry distribution chart, Double Bond Pharmaceutical International AB ranks #865 out of 1409 companies in the Biotechnology industry, placing it in the top 61.4%.
Is Double Bond Pharmaceutical International AB's FCF Yield % too high?
Double Bond Pharmaceutical International AB's current FCF Yield % is -15.56. Based on the distribution chart, Double Bond Pharmaceutical International AB ranks #865 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Double Bond Pharmaceutical International AB has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Double Bond Pharmaceutical International AB's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Double Bond Pharmaceutical International AB ranks #865 out of 1409 companies for FCF Yield %. This places Double Bond Pharmaceutical International AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Double Bond Pharmaceutical International AB and its competitors. Double Bond Pharmaceutical International AB's current FCF Yield % is -15.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Double Bond Pharmaceutical International AB stock overvalued right now?
Based on GuruFocus' analysis, Double Bond Pharmaceutical International AB (XSAT:DBP B) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.06, compared to a current price of kr0.14 — trading 125.8% above its estimated fair value. The current FCF Yield % is -15.56. Double Bond Pharmaceutical International AB's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Double Bond Pharmaceutical International AB (XSAT:DBP B), the current FCF Yield % is -15.56 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Double Bond Pharmaceutical International AB (XSAT:DBP B) Overvalued in 2026?
Based on GuruFocus' analysis, Double Bond Pharmaceutical International AB stock appears to be overvalued.
The current stock price of kr0.14 is trading 125.8% above its estimated GF Value™ of kr0.06.
GuruFocus considers Double Bond Pharmaceutical International AB to be Significantly Overvalued.
Key valuation signals for XSAT:DBP B:
FCF Yield %: -15.56
GF Value™: kr0.06 vs. price of kr0.14 (125.8% above fair value)
No single metric tells the full story. See the XSAT:DBP B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Double Bond Pharmaceutical International AB Business Description
Double Bond Pharmaceutical International AB is a pharmaceutical company. The company develops and commercializes approaches for the treatment of cancers, infections, autoimmune diseases, and other life-threatening disorders.
30GF Score
Get the complete analysis for XSAT:DBP B
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:DBP B has been successfully added to your 
